Innocan Pharma Private Placement of Units
Analysis based on 14 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026
The private placement is a modest capital raise for Innocan Pharma, providing up to C$1 million in working capital. The offering may slightly dilute existing shareholders but signals continued operational funding, with a neutral to slightly positive impact on the company's liquidity.
Innocan Pharma Corporation announced on September 9, 2026 its intention to complete a private placement of up to 535,000 units at C$1.87 per unit, for gross proceeds of up to C$1,000,000. Each unit consists of one common share and one common share purchase warrant, with each warrant exercisable at C$2.50 for three years. The offering is expected to close on or around September 17, 2026. Proceeds will be used for working capital and general corporate purposes. The company will pay a finder's fee of 10% in cash and 8% finder's warrants to arm's length finders. Securities issued will be subject to a four-month-and-one-day hold period. The offering is not registered in the United States.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard